MiR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting.

ABSTRACT:

Background

5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive.

Methods

miR-182 promoter methylation was measured in 94 AZA + VEN-treated elderly or unfit AML patients and 20 normal controls (NCs) samples. To determine whether miR-182 promoter methylation is a predictive marker of clinical outcomes in AZA + VEN-treated AML patients in a real-world setting, we analyzed and compared the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate, overall survival (OS), and leukemia free-survival (LFS)

SUBMITTER: Xu Y 

PROVIDER: S-EPMC11800541 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature